anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lung transplantation is increasingly employed as a therapy for patients with advanced lung disease including cystic fibrosis, idiopathic pulmonary fibrosis or emphysema. Despite significant short-term improvements in life quality and measures of lung function after lung transplantation, long-term outcomes are disappointing primarily due to the development of a condition of airway fibrosis known as bronchiolitis obliterans (BO). It is hypothesized that aztreonam lysine for inhalation (AZLI) is a safe and effective treatment for declining lung function in lung transplant recipients with early stage BOS. In order to test the hypothesis, the investigators seek to establish the safety of AZLI in a two-center cohort of 30 lung transplant recipients with BOS treated intermittently for 5 consecutive study months and determine if this treatment leads to improvement or stabilization of lung function. The intervention will involve open label treatment with AZLI, in addition to usual transplant care, administered for 3 intermittent courses, 28 days each, over a 5 month study period.. Bronchoscopy, pulmonary function testing, and laboratory testing will be performed on a regular basis during study enrollment consistent with each center's usual standard clinical care. Patients will have a baseline screening visit, one month and five month study visit.. The study will take two years to complete from the start of funding. After a start-up period of 2 months, a total of 30 patients will be enrolled over 12 months across the two centers (15 patients each at DUMC and UCLA). Each enrolled patient will complete 5 months of intermittent therapy, and complete baseline, month 1 and month 5 visits. Over the next 6 months the study database will be finalized, statistical analysis will for primary and secondary outcomes will be performed leading to the generation of either a study abstract or manuscript.
This randomized clinical trial will be conducted at the Children's Hospital. The sample size will consist of 34 participants. Participants who meet the inclusion criteria will be randomly allocated into two groups using an online randomization tool; Group A will receive modified constraint-induced movement therapy with electrical stimulation and Group B will receive modified constraint-induced movement therapy only. Both groups will receive routine physical therapy as a part of treatment. All participants will receive a 60-minute session, 6 times a week for 16 weeks.

Universal Goniometer will be used to assess range of motion, the Medical Research Council Scale for muscle strength, and the Active Movement Scale for motor function at baseline, 4th, 8th, 12th, and 16th weeks after treatment discontinuation. The data will be analyzed using SPSS version 26 for Windows software.
Osteoarthritis is a prevalent musculoskeletal disease that involves cartilage degradation, subchondral bone remodeling, and synovial inflammation and ultimately causes physical disability. Common risk factors for osteoarthritis include age, sex, obesity, and genetic predispositions. Treatment includes nonpharmaceutical and pharmacological approaches; however, disease-modifying osteoarthritis drugs remain undeveloped. We aimed to identify key regulatory factors underlying the etiology of osteoarthritis. We studied alterations of the inflammatory responses after manipulating the expression of MTLN, which we selected after sequencing and transcriptomics of the patients' synovial tissues. MTLN expression was increased in synovial tissues of patients and in SW982 human synovial sarcoma cells following inflammatory stimuli. We found that MTLN overexpression or knockout respectively decreased or increased expression of the inflammation-associated genes, including IL-6, IL-8, and TNF-α. Thus, high levels of MTLN in osteoarthritis may protect tissues against excessive inflammation, thereby offering therapeutic potentials.
The invention relates to compositions comprising cell culture medium conditioned by cells grown in three-dimensional culture. The cells used to condition the medium may be genetically modified to alter the concentration of growth factors and antioxidants in the medium. The conditioned cell medium (conditioned medium) may be used for at least one of cosmetic applications, cosmeceutical applications, and pharmaceutical applications, among other things. The invention also relates to proteins comprising a heterologous sequence that enhances cell penetration. The invention also relates to cells comprising DNA encoding such proteins. Methods for preparing the inventive compounds are also provided.
The invention relates a lactic acid bacteria nasal wash comprising a diluent and at least one lactic acid bacterium. The total content of the lactic acid bacteria is not less than 100 cfu/ml. The nasal wash can be used to wash the nose, clearing nasal cavity dirt and improving the relative ratio of lactic acid bacteria in the nasal cavity, thereby increasing the ratio of beneficial bacteria in upper and lower respiratory tracts. The nasal wash can be used to wash the nose, improving original bacterial imbalance in the nasal cavity, reconstructing normal flora in respiratory tracts and reducing respiratory inflammations and allergies. Meanwhile, in continuous ciliary movement, the nasal wash also helps supplement high-activity probiotics for gastrointestinal tracts through the respiratory tract mucous blanket. The nasal wash is a new means to improve flora in the respiratory system and digestive system and is well functional in preventing and treating upper and lower respiratory tract diseases caused by microorganisms. New uses and a new applicable field are developed for lactic acid bacteria.
PURPOSE:To obtain a skin drug for external use, containing an ester consisting of disproportionated rosin and/or hydrogenated rosin, a fatty acid and polyhydric alcohol, used as an oily raw material for cosmetics, etc., and having good oxidation stability as well as excellent touch in use without sensitizing property to the skin. CONSTITUTION:A skin drug for external use containing an ester consisting of disproportionated and/or hydrogenated rosin, a fatty acid and polyhydric alcohol as an active ingredient. The above-mentioned ester is obtained by normally reacting rosin (resin available from pines and oaks) in the presence of a catalyst, e.g. palladium, nickel, etc., at a high temperature of 200-300 deg.C to carry out disproportionation or hydrogenation and esterifying the resultant product with a fatty acid and polyhydric alcohol. The amount of the ester blended in the titled drug for external use is 0.1-70wt.%, preferably 1-50wt.%. Furthermore, the esters include high-melting to low-melting esters. The high- melting esters are used by dissolving in liquid substances, e.g. liquid paraffin, etc.
Total and segmental body fluid volumes (total water, extracellular water and interstitial water) will be measured by Segmental Bioelectrical Impedance Spectroscopy (as per manufacturer instructions of use). Areas with most significant oedema and skin in a suitable condition shall be selected for the TFR application. Moisture Meter shall be used at the selected site to measure the skin water content at 4 depths (0.5mm, 1.5mm, 2.5mm and 5mm).
Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
The invention discloses an escherichia coli engineering bacterium for synthesizing an escherichia coli glycoprotein conjugate vaccine for neonatal meningitis and application thereof. Relates to a method for constructing a cell factory for synthesizing Escherichia coli O1 serotype glycoprotein conjugate vaccine for causing neonatal meningitis. The O1 antigen synthetic gene cluster plasmid is constructed by utilizing the efficient homologous recombination efficiency of saccharomyces cerevisiae and based on a DNA Assembler method. Transforming O1 antigen into shuttle plasmid of synthetic gene cluster in Escherichia coli JM109, extracting lipopolysaccharide, performing gel electrophoresis and identifying plasmid by silver staining; deletion in JM109 with the aid of FLP-FRT waaL And wecA and eliminating the interference of original incomplete O antigen. The pET28a (+) plasmid was engineered, induced, glycoprotein-binding vaccines were synthesized, glycoproteins were purified by means of the AKTA Primeplus protein purification workstation and identified by western-blotting. The recombinant escherichia coli constructed by the invention provides a new idea for synthesizing glycoprotein conjugate vaccine by a biological method.
BACKGROUND: Polycystic ovary syndrome (PCOS) is a gynecological endocrine disease and could be considered a metabolic disease because it is often accompanied by obesity and insulin resistance. Brown adipose tissue (BAT) transplantation has been shown to be effective in treating PCOS rats.
RESULTS: The study demonstrated that BAT successfully recovered the reproductive and metabolic phenotype of PCOS rats. The disorder estrous cycle, abnormal hyperglycemia and the expression of liver factors were improved. Differentially expressed metabolites were analyzed, among them, arachidonic acid may play a role in inhibiting cell proliferation, enhancing oxidative stress reaction, promoting estrogen expression, and reducing progesterone level in KGN cells.
CONCLUSION: Our findings suggest that BAT transplantation may be a therapeutic strategy for PCOS by changing the expression of some cytokines and metabolites. Differentially expressed metabolites might be crucially important for the pathogenesis of PCOS.
Total caloric intake aimed at maintaining a diet with\> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day. 3 sessions per week on a bicycle ergometer or on a treadmill (according to body fat distribution and other parameters) modifications carried out weekly, with a gradual increase as to exercise until maximal oxygen consumption 60 - 70% would always preceded by heating 5 minutes.
BACKGROUND: Oral lichen planus (OLP) and oral epithelial dysplasia (OED) present diagnostic challenges due to clinical and histologic overlap. This study explores the immune microenvironment in OED, hypothesizing that immune signatures could aid in diagnostic differentiation and predict malignant transformation.
METHODS: Tissue samples from OED and OLP cases were analyzed using immunofluorescence/immunohistochemistry (IF/IHC) for CD4, CD8, CD163/STAT1, and PD-1/PDL-1 expression. RNA-sequencing was performed on the samples, and data was subjected to CIBERSORTx analysis for immune cell composition. Gene Ontology analysis on the immune differentially expressed genes was also conducted.
RESULTS: In OED, CD8 + T-cells infiltrated dysplastic epithelium, correlating with dysplasia severity. CD4 + lymphocytes increased in the basal layer. STAT1/CD163 + macrophages correlated with CD4 + intraepithelial distribution. PD-1/PDL-1 expression varied. IF/IHC analysis revealed differential immune cell composition between OED and OLP. RNA-sequencing identified upregulated genes associated with cytotoxic response and immunosurveillance in OED. Downregulated genes were linked to signaling, immune cell recruitment, and tumor suppression.
CONCLUSIONS: The immune microenvironment distinguishes OED and OLP, suggesting diagnostic potential. Upregulated genes indicate cytotoxic immune response in OED. Downregulation of TRADD, CX3CL1, and ILI24 implies dysregulation in TNFR1 signaling, immune recruitment, and tumor suppression. This study contributes to the foundation for understanding immune interactions in OED and OLP, offering insights into future objective diagnostic avenues.
A convenience sample will be utilized to obtain subjects. Subjects will be given a brief questionnaire to identify possible contraindications for manual therapy treatment techniques and exclude individuals if necessary. Subjects will be randomized into one of eight groups (three variables, each with two conditions including: therapist gender match/mismatch, lab coat worn/not worn, detailed explanation/colloquial conversation about the technique) and participate in neurodynamic testing for the upper quarter via the Upper Limb Provocation Test. Subjects who are determined to be positive for one or more extremities will receive a sham thoracic spine manipulation technique. After application of the technique, previously positive limbs will be retested. Individuals who respond favorably to the sham technique upon reassessment will participate in an exit interview with open-ended questions in attempt to gain more insight into the factors which may have influenced their neurodynamic mobility improvement.
Idiopathic sudden sensorineural hearing loss (ISSNHL) is one of the most common diseases in otolaryngology. Its etiology remains unknown. Furthermore, there is only a low level of evidence for the efficacy of established treatment modalities. In addition to systemic glucocorticoids, intratympanic corticosteroid treatment (ICT) has become increasingly important for treatment of ISSNHL. Different application strategies and treatment regimens have been described; however, uniform standards do not yet exist. ICT may be used for primary treatment as well as salvage therapy. Current data from meta-analyses show no benefit of intratympanic versus systemic primary therapy for sudden hearing loss (moderate evidence) but suggest a benefit of intratympanic secondary treatment over no treatment or placebo (high effect size, low evidence). Regarding combination of systemic and local glucocorticoid therapy in primary treatment of hearing loss, there may be a small benefit over systemic treatment alone (low effect size, low evidence).
The present invention relates to an apparatus ( 26 ) and a method for determining a fractional flow reserve. For this purpose, a new personalized hyperemic boundary condition model is provided. The personalized hyperemic boundary condition model is used to condition a parametric model for a simulation of a blood flow in a coronary tree ( 34 ) of a human subject. As a basis for the personalized hyperemic boundary condition model, a predefined hyperemic boundary condition model is used, which represents empirical derived hyperemic boundary condition parameters. However, these empirical hyperemic boundary condition parameters are not specific for a human subject under examination. In order to achieve a specification of the respective predefined hyperemic boundary condition model, specific human subject features are derived from a volumetric image of the coronary tree of the human subject. These features are used to adjust the predefined hyperemic boundary condition model resulting in a personalized hyperemic boundary condition model. As an effect, a flow simulation using the parametric model conditioned by the personalized hyperemic boundary condition model. As an effect, a flow simulation using the parametric model conditioned by the personalized hyperemic boundary condition model improves the performance of flow simulation in order to determine an enhanced fractional flow reserve.
There will be two measurements. One measurement of MVIC and quick flicks will be done in a standing and supine position with 3 repetitions. The TrakSTARTM, Ultrasound, surface EMG and Accelerometer will measure the PFM movements and activation simultaneously. The Ultrasound is measured from one tester (to guaranty a high intratester reliability) (Sherburn et al., 2005).

TrakSTARTM, surface EMG and Accelerometer will measure 3 Trampoline jumps. The measurements will be done once during one hour. The women will insert the vaginal probe by themselves and stay dressed during the measurement procedure. The measurements will be done in a standardized way. All the arrangements are made to ensure the hygiene requirements.
Participants randomized to this arm will receive pedometers, weekly prompts, and 6 motivational text messages a week. They will participate in baseline and 3 months data collection.
Anodic transcranial direct current stimulation (tDCS) over left dorsolateral prefrontal cortex (DLPFC) associated with cognitive training (Tcog). Duration: 20 minutes; Intensity: 2mA.
In a descriptive, prospective, blinded image interpretation study 2 of adult patients with known or suspected coronary artery disease, myocardial perfusion deficits in stress and rest PET images obtained with Ammonia N 13 (N=111) or Rubidium 82 (N=82) were compared to changes in stenosis flow reserve (SFR) as determined by coronary angiography. The principal outcome of the study was the evaluation of PET defect severity relative to SFR. 

PET perfusion defects at rest and stress for seven cardiac regions(anterior, apical, anteroseptal, posteroseptal, anterolateral, posterolateral, and inferior walls) were graded on a 0 to 5 scale defined as normal (0), possible (1), probable (2), mild (3), moderate (4), and severe (5) defects. Coronary angiograms were used to measure absolute and relative stenosis dimensions and to calculate stenosis flow reserve defined as the maximum value of flow at maximum coronary vasodilatation relative to rest flow under standardized hemodynamic conditions. SFR scores ranged from 0 (total occlusion) to 5 (normal). 

With increasing impairment of flow reserve, the subjective PET defect severity increased. A PET defect score of 2 or higher was positively correlated with flow reserve impairment (SFR<3).
Patient received cidofovir due to clinical necessity (therapy resistant HCMV retinitis) while being on continuous hemofiltration. Pre- and postfilter plasma samples were taken at multiple timepoints during 24 hours.
Intervention meetings surrounding supervised exercise therapy (SET) will occur individually with participants in a 1:1 format once per week for 30 minutes over 8 weeks. Additionally, participants will be encouraged to practice exercises at home at least 2 additional days between intervention meetings using visual handouts (up to 7 times/week total, approximately 140 minutes/week).
Participants will receive mycophenoate mofetil, daclizumab, and corticosteroids (prednisolone) for 3 to 12 months. Participants will also receive cyclosporine which will be replaced with sirolimus at later stage of the study.
Individual data of 336 patients with locally advanced cervical cancer treated with surgical staging at our institution from January 2020 to August 2022 were pooled analysed. The following factors were collected from each patient to identify variables predicting para-aortic lymph node metastasis: age, T-staging，histopathological type，tumor size, differentiation, pretreatment tumor markers (squamous carcinoma antigen, carcinoembryonic antigen, Carbohydrate antigen 125 and cytokeratin fragment 21-1 , human papilloma virus type, the status of pelvic lymph node on images, common iliac lymph node and the short-axis diameter of the largest positive and the status of para-aortic lymph node on surgical staging results. Multivariate Logistic regression analysis was used to develop the prediction model. A simplified scoring system for each independent predictive factors was developed according to its coefficient. Internal validation was performed to assess the model. An independent validation cohort contained 116 patients with the same criteria from March 2018 to December 2019.
Patients are allowed to use their SABA as rescue medication only. During the last 4 weeks, the patients will receive 400 microgram of Qvar.
cDNA libraries may be obtained from neural cell cultures produced by using growth factors to induce the proliferation of multipotent neural stem cells. The libraries may be obtained from both cultured normal and dysfunctional neural cells and from neural cell cultures at various stages of development. This information allows for the identification of the sequence of gene expression during neural development and can be used to reveal the effects of biological agents on gene expression in neural cells. Additionally, nucleic acids derived from dysfunctional tissue can be compared with that of normal tissue to identify genetic material which may be the cause of the dysfunction. This information could then be used in the design of therapies to treat the neurological disorder. A further use of the technology would be in the diagnosis of genetic disorders or for use in identifying neural cells at a particular stage in development.
The invention discloses a medicine for treating erysipelas. The medicine is characterized by consisting of the following medicinal raw materials in parts by weight: 400-900g of lysimachia christinae hance, 200-430g of manyleaf paris rhizome, 30-70g of grubs, 8-24g of tobacco tar and 100-300g of cortex castaneae mollissimae. As an optimum scheme, the medicine disclosed by the invention, the medicine consists of the following medicinal raw materials in parts by weight: 600g of lysimachia christinae hance, 300g of manyleaf paris rhizome, 50g of grubs, 16g of tobacco tar and 200g of cortex castaneae mollissimae. A preparation method comprises the following steps: heating 2000g of the Vaseline in a pot to 280-320 DEG C, removing impurities of the lysimachia christinae hance, the manyleaf paris rhizome and the cortex castaneae mollissimae, separating the lysimachia christinae hance, the manyleaf paris rhizome and the cortex castaneae mollissimae into 3-5 parts, frying each part in the pot until the part is dried up and then taking out the fried part and frying the other part until each part is sequentially fried; frying the grubs in the pot until the grubs are dried up, then removing impurities in the pot, adding the tobacco tar to the pot when the materials in the pot are still hot, uniformly stirring and cooling so as to obtain the medicine. A using method is as follows: the medicine is externally applied to a sore surface by a thickness of 3mm and is changed once every day. Skin on the focus of erysipelas is completely cleaned and the ointment disclosed by the invention is smeared on festers by virtue of a cotton swab, wherein the ointment is smeared on the entire focus of the erysipelas.
Dupilimab: 600 mg, given as two 300 mg subcutaneous injections on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.